Bayer AG’s Bayer HealthCare And Onyx Announce Submission Of FDA And Ema Applications For Nexavar Treatments-DJ


Monday, 1 Jul 2013 02:30am EDT 

Dow Jones reported that Bayer AG’s Bayer HealthCare and Onyx Pharmaceuticals Inc announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and an application for marketing authorization to the European Medicines Agency (EMA) for the oral multi-kinase inhibitor Nexavar(sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer. 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014